These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2918046)

  • 1. Distribution of RU 486 and its demethylated metabolites in humans.
    Heikinheimo O; Haukkamaa M; Lähteenmäki P
    J Clin Endocrinol Metab; 1989 Feb; 68(2):270-5. PubMed ID: 2918046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
    Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
    J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.
    Heikinheimo O
    J Steroid Biochem; 1989 Jan; 32(1A):21-5. PubMed ID: 2913396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and serum binding of RU 486 in women after various single doses.
    Heikinheimo O; Lähteenmäki PL; Koivunen E; Shoupe D; Croxatto H; Luukkainen T; Lähteenmäki P
    Hum Reprod; 1987 Jul; 2(5):379-85. PubMed ID: 3654927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationships of RU 486.
    Heikinheimo O; Kekkonen R
    Ann Med; 1993 Feb; 25(1):71-6. PubMed ID: 8382070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans.
    Heikinheimo O; Croxatto H; Salvatierra AM; Chang CC; Luukkainen T; Lähteenmäki P
    Hum Reprod; 1987 Nov; 2(8):645-8. PubMed ID: 3437043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of RU 486.
    Lähteenmäki P; Heikinheimo O; Croxatto H; Spitz I; Shoupe D; Birgerson L; Luukkainen T
    J Steroid Biochem; 1987; 27(4-6):859-63. PubMed ID: 3695508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose.
    Cekan S; Aedo AR; Segerstéen E; Van Look P; Messinis I; Templeton A
    Hum Reprod; 1989 Feb; 4(2):131-5. PubMed ID: 2918065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiprogesterone steroid RU486. Pharmacokinetics and receptor binding in humans.
    Heikinheimo O
    Acta Obstet Gynecol Scand; 1990; 69(4):357-8. PubMed ID: 2244471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans.
    Heikinheimo O; Kontula K; Croxatto H; Spitz I; Luukkainen T; Lähteenmäki P
    J Steroid Biochem; 1987 Feb; 26(2):279-84. PubMed ID: 3560943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the antiprogesterone RU 486: no correlation to clinical performance of RU 486.
    Heikinheimo O; Ylikorkala O; Turpeinen U; Lähteenmäki P
    Acta Endocrinol (Copenh); 1990 Sep; 123(3):298-304. PubMed ID: 2239078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle.
    Permezel JM; Lenton EA; Roberts I; Cooke ID
    J Clin Endocrinol Metab; 1989 May; 68(5):960-5. PubMed ID: 2497130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the progesterone antagonist RU486 on human myometrial spontaneous contractility and PGI2 release.
    Lobaccaro-Henri C; Saintot M; Laffargue F; Zahradnik HP; Descomps B; Thaler-Dao H
    Prostaglandins; 1992 Nov; 44(5):443-55. PubMed ID: 1470683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of RU 486 and its active metabolites in humans].
    Földesi I; Falkay G; Kovács L
    Acta Pharm Hung; 1994 Jan; 64(1):17-21. PubMed ID: 8023681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic metabolism and distribution of mifepristone and its metabolites in rats.
    Heikinheimo O; Pesonen U; Huupponen R; Koulu M; Lähteenmäki P
    Hum Reprod; 1994 Jun; 9 Suppl 1():40-6. PubMed ID: 7962468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.
    Thomas M; Monet JD
    J Clin Endocrinol Metab; 1992 Sep; 75(3):865-70. PubMed ID: 1517379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women.
    Shi YE; Ye ZH; He CH; Zhang GQ; Xu JQ; Van Look PF; Fotherby K
    Contraception; 1993 Aug; 48(2):133-49. PubMed ID: 8403910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man.
    Kawai S; Nieman LK; Brandon DD; Udelsman R; Loriaux DL; Chrousos GP
    J Pharmacol Exp Ther; 1987 May; 241(2):401-6. PubMed ID: 3572801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.